Zubsolv

Pain, Itching, Septic Shock + 7 more

Treatment

8 FDA approvals

20 Active Studies for Zubsolv

What is Zubsolv

Naloxone

The Generic name of this drug

Treatment Summary

Buprenorphine is a medication used to treat severe pain and opioid addiction. It is sold under the name Suboxone and is formulated with naloxone, a drug that blocks the effects of opioids if injected. Buprenorphine is taken sublingually (under the tongue) and works by binding to opioid receptors in the brain to reduce pain or withdrawal symptoms. It has a long-lasting effect and can be taken once a day, which reduces the risk of overdose or side effects. Buprenorphine is also used in Opioid Agonist Treatment (OAT) or Opioid Subst

Narcan

is the brand name

image of different drug pills on a surface

Zubsolv Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Narcan

Naloxone

1971

241

Approved as Treatment by the FDA

Naloxone, otherwise called Narcan, is approved by the FDA for 8 uses including Pain and Opioid Dependence .

Pain

Used to treat moderate Pain in combination with Pentazocine

Opioid Dependence

Used to treat Opioid Dependence in combination with Buprenorphine

Septic Shock

Pain

Used to treat Severe Pain in combination with Pentazocine

Opioid-Related Disorders

Used to treat Opioid Dependence in combination with Buprenorphine

Septic Shock

Opioids

Respiratory Insufficiency

Effectiveness

How Zubsolv Affects Patients

Buprenorphine is an opioid painkiller that works by binding to mu-receptors in the brain, spine, and other parts of the body. It can produce feelings of relaxation, euphoria, and drowsiness, as well as reduce coughs and shrink pupil size. Taking buprenorphine for a long period of time can lead to physical dependence, with withdrawal symptoms when it is stopped suddenly. It can also cause significant respiratory depression and even death if taken in large doses or when combined with other substances like benzodiazepines or alcohol. Buprenorphine can cause constipation, decreased sex drive

How Zubsolv works in the body

Buprenorphine is a drug that binds to the same nerve receptors as other opioids, like heroin, oxycodone and methadone. However, it doesn't activate these receptors as much as these other opioids, which means it has a slower onset and a "ceiling effect" - a point at which the effects of the drug stop increasing. This makes it less likely to cause overdose, and the lower activation of the receptors means it doesn't cause as much sedation or euphoria. Buprenorphine can cause a rapid withdrawal if taken by someone who's already dependent on opioids, so it's important that they

When to interrupt dosage

The measure of Zubsolv depends on the diagnosed affliction, including Pain, Pain and Opioid Dependence. The quantity of dosage likewise varies as indicated by the method of delivery (e.g. Tablet - Oral or Sublingual) specified in the table beneath.

Condition

Dosage

Administration

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Itching

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioid-Related Disorders

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Septic Shock

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Respiratory Insufficiency

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Pain

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Emergency Care

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Pain

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Warnings

Zubsolv has twenty-two contraindications and should not be ingested when enduring any of the ailments outlined in the subsequent table.

Zubsolv Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Naloxone may interact with Pulse Frequency

There are 20 known major drug interactions with Zubsolv.

Common Zubsolv Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Naloxone.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Naloxone.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Naloxone.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Naloxone.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Naloxone.

Zubsolv Toxicity & Overdose Risk

Signs of an acute overdose of morphine include small pupils, drowsiness, low blood pressure, and difficulty breathing. If left untreated, it can lead to death.

image of a doctor in a lab doing drug, clinical research

Zubsolv Novel Uses: Which Conditions Have a Clinical Trial Featuring Zubsolv?

Currently, 21 active studies are assessing the potential of Zubsolv for treating Opioid Dependence, Pain and Palliative Care.

Condition

Clinical Trials

Trial Phases

Emergency Care

0 Actively Recruiting

Opioids

0 Actively Recruiting

Opioid-Related Disorders

0 Actively Recruiting

Septic Shock

0 Actively Recruiting

Respiratory Insufficiency

0 Actively Recruiting

Itching

2 Actively Recruiting

Phase 3, Not Applicable

Pain

0 Actively Recruiting

Opioids

7 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 1

Opioids

6 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 4

Pain

0 Actively Recruiting

Zubsolv Reviews: What are patients saying about Zubsolv?

5

Patient Review

4/6/2017

Zubsolv for Narcotic Addiction

Zubsolv has been a game-changer for me. I was on suboxone twice before and relapsed both times, but this third time feels different. Zubsolv doesn't make me feel as terrible as suboxone did, and I'm finally starting to see progress in my recovery.

5

Patient Review

4/7/2017

Zubsolv for Prevention of Opiate Drug Abuse

I feel like this drug has helped me more than any other I've tried. Zubsolv is definitely the way to go if you're looking to get off drugs.

5

Patient Review

7/30/2014

Zubsolv for Narcotic Addiction

I switched from Sub to Zub on 7/1/14 when my insurance stopped covering the former. I find Zub WAY more effective: it tastes better, dissolves faster, and gets into my bloodstream quickly. I was on 16mg Sub and now 10mg of Zub and can tell NO difference. The only downside is that it's hard to open the package.

5

Patient Review

5/1/2019

Zubsolv for Prevention of Opiate Drug Abuse

This medication has been integral in my sobriety. It curbs cravings and helps me feel more confident about my ability to stay clean. I highly recommend it to anyone who is addicted or trying to stay sober.

5

Patient Review

12/11/2019

Zubsolv for Narcotic Addiction

These pills have completely changed my life for the better. I highly recommend them to anyone struggling with addiction.

4.7

Patient Review

7/31/2015

Zubsolv for Narcotic Addiction

I've been on zubsolv for almost a year now and I much prefer it to sub. To me, it lasts longer and tastes better. Additionally, I get a bit of a rush from it unlike sub which made me incredibly tired. The only problem with zub is that my pharmacy isn't always well-stocked with it.

4

Patient Review

7/31/2017

Zubsolv for Narcotic Addiction

Suboxone is my preferred treatment, but Zubsolv works just as well. The only downside is that the tablets are not as easy to use as the strips.

1.7

Patient Review

11/11/2022

Zubsolv for Chronic Pain

Subutol was a terrible experience for me. It made my headaches and muscle pain in my legs worse, sapped all my energy, and made it hard to get out of bed or focus on anything. I got back on Suboxone and within two days felt one hundred percent better.

1.3

Patient Review

8/3/2015

Zubsolv for Chronic Pain

Suboxone was a huge disappointment. I experienced intense water retention, raw tongue and swelling, lethargy, lack of energy, withdrawal symptoms, no pain relief, vision problems, constipation, irritability, and difficulty opening the packaging.

1

Patient Review

1/18/2015

Zubsolv for Prevention of Opiate Drug Abuse

I was recently switched to Zubsolv because my insurance stopped covering name brand Suboxone films and then the generic Suboxone tablets. I hate the minty taste and i've been depressed since switching last week. I have been having trouble sleeping and for the first time in years i'm experiencing withdrawls again.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zubsolv

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Zubsolv?

"You may experience the following symptoms: dizziness, drowsiness, blurred vision, feeling drunk, trouble concentrating, withdrawal symptoms, tongue pain, redness or numbness inside your mouth, nausea, vomiting, constipation, headache, back pain, fast or pounding heartbeats, increased sweating, or sleep problems (insomnia)."

Answered by AI

How does Zubsolv make you feel?

"However, people taking buprenorphine in studies have reported some emotional side effects, such as anxiety, depression, and nervousness. Additionally, people going through withdrawal may also experience these emotions. withdrawal from buprenorphine can cause anxiety."

Answered by AI

What is Zubsolv used for?

"Naloxone reverses the effects of opioids and can cause withdrawal symptoms in people who take opioids.

This drug is a combination of two medicines, buprenorphine and naloxone, and is used to treat dependence or addiction to opioids. Buprenorphine is a drug that belongs to a class of mixed opioid agonist-antagonists, meaning that it helps to prevent withdrawal symptoms caused by quitting other opioids. Naloxone, on the other hand, reverses the effects of opioids and can actually cause withdrawal symptoms in people who take opioids regularly."

Answered by AI

Does Zubsolv have Narcan in it?

"Zubsolv contains two active drugs: buprenorphine and naloxone. Zubsolv comes in six strengths, which contain different amounts (in milligrams) of the drugs. The lowest strength contains 0.7 mg of buprenorphine and 0.18 mg of naloxone."

Answered by AI

Clinical Trials for Zubsolv

Image of Therapeutics Initiative - Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia in Vancouver, Canada.

Educational Interventions for Opioid Use in Dentistry

Any Age
All Sexes
Vancouver, Canada

The aim of this study is to estimate the impact of providing personalized prescribing data and educational materials on opioid prescribing to dentists in British Columbia, Canada. The main research questions are: 1. What is the impact of an intervention on the use of opioids for dental pain? The intervention includes a personalized prescribing report (a "Portrait"), brief educational summary, and patient education materials; and 2. Does the impact of the intervention increase when dentists are also invited to attend facilitated audit-and-feedback group sessions and to develop a practice improvement plan? Using administrative health data, the prescribing of those in different combinations of materials in the Early Group will be compared to those in the Delayed Group to estimate the impact of the materials on prescribing by the dentists.

Waitlist Available
Has No Placebo

Therapeutics Initiative - Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia

Colin Dormuth, ScD

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Have you considered Zubsolv clinical trials?

We made a collection of clinical trials featuring Zubsolv, we think they might fit your search criteria.
Go to Trials
Image of Toronto General Hospital in Toronto, Canada.

Transcutaneous Electrical Stimulation for Slow Breathing

18+
All Sexes
Toronto, Canada

After surgery, patients often recover in a special area called the Post Anesthesia Care Unit (PACU). Patients may receive pain medications either during the surgery or afterward in the PACU. While these medications are important for controlling pain, some of them can slow down breathing. To ensure patients' breathing remains safe, the nurses in the PACU monitor respiratory rate (how many breaths a patient takes per minute) and oxygen levels using standard monitoring equipment. This is the usual way they check for breathing concerns. If these monitors show that a patient's breathing has slowed down too much, nurses may wake the patient up or stimulate them using their voice or gentle physical touch to encourage deeper breaths. What is this study about? This research is testing a new approach that uses an additional monitor called capnography. Capnography helps detect slowing or stopping of breathing by measuring the carbon dioxide (CO2) exhaled by patients. If the monitor shows slowed or stopped breathing (called apnea, lasting at least 10 seconds), this study will test using a technology called transcutaneous electrical stimulation (TES) to encourage normal breathing. How does TES work? TES provides a slight, annoying sensation on the patient's skin-enough to wake them up without causing pain. This has been used in other studies to safely restore breathing after surgery. In this study, the researchers are testing whether a new automated device can deliver TES when the capnography monitor detects breathing issues. The goal is to test the feasibility (can this system work in the PACU?) and acceptability (how do patients feel about this approach?) of this technology. Who can join this study? Adults aged 18 or older who received general anesthesia and medications (opioids) for pain control during or after surgery are eligible. Patients recovering from surgery in the PACU at Toronto General Hospital may be invited to participate. Why is this study important? The study aims to reduce the risk of opioid-related breathing problems after surgery, making recovery safer and more comfortable for patients.

Recruiting
Has No Placebo

Toronto General Hospital

Have you considered Zubsolv clinical trials?

We made a collection of clinical trials featuring Zubsolv, we think they might fit your search criteria.
Go to Trials
Image of Pennsylvania Psychiatric Institute in Harrisburg, United States.

Semaglutide for Opioid Addiction

18 - 75
All Sexes
Harrisburg, PA

The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: * Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study

Phase 2
Recruiting

Pennsylvania Psychiatric Institute (+2 Sites)

Jennifer Nyland, PhD

Have you considered Zubsolv clinical trials?

We made a collection of clinical trials featuring Zubsolv, we think they might fit your search criteria.
Go to Trials